US rejection is a rude awakening for Lundbeck
In a surprising turn of events, the US FDA decided not to approve the antidepressant Brintellix from Lundbeck and Takeda. It could erode the drug’s commercial potential, says an analyst from Sydbank.
BY ELIZABETH MØNSTED JOHANSEN
Most observers had expected that the US Food and Drug Administration (FDA) would approve a label expansion for the antidepressant Brintellix from Lundbeck and Takeda this week.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Lundbeck CSO: Label expansion will ease communication
For abonnenter
Lundbeck CSO: It will have a huge impact
For abonnenter
Promising signs from Lundbeck’s depression drug
For abonnenter
